Normal view MARC view ISBD view

Efficacy,safety, and cost-effectiveness of biosimilars of bevacizumab in naive patients with diabetic macular edema

Shalini virani

Efficacy,safety, and cost-effectiveness of biosimilars of bevacizumab in naive patients with diabetic macular edema - PP248-252

Subjects--Facted Index Terms:
Anti-vascular endothelial growth factor
bevacizumab
biosimilars
cost-effectiveness
diabetic macular edema

Place hold
Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

SNDT WOMEN'S UNIVERSITY

BMK Knowledge Resource Centre

Efficacy,safety, and cost-effectiveness of biosimilars of bevacizumab in naive patients with diabetic macular edema